Lundbeck's corporate venturing unit has co-led company's series A round, and the funds will be used to develop the pipeline for its two lead treatment options.
Lundbeckfond Ventures, the venture capital fund owned by Denmark-based pharmaceutical company Lundbeck, and VC firm 5AM Ventures have co-led a $16m series A round for US-based biopharmaceutical company scPharmaceuticals.
scPharmaceuticals creates innovative and important new therapeutic options that make time-released drug administration easy and convenient enough for both clinical situations and self-application without the need for intravenous needles.
The funds will allow the company to continue building a pipeline behind its two lead programs: a cephalosporin antibiotic and a drug-device…
